Detalhe da pesquisa
1.
Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach.
Br J Clin Pharmacol
; 90(5): 1333-1343, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38403473
2.
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
Int J Cancer
; 151(11): 1978-1988, 2022 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833561
3.
Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies.
Radiology
; 305(3): 565-574, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35880977
4.
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
Gynecol Oncol
; 155(2): 262-269, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31604666
5.
Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
Breast Cancer
; 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38600429
6.
Errors in prescribing injectable anticancer drugs: benefits of a pharmaceutical long-term monitoring to improve patient safety in a European comprehensive cancer centre.
Eur J Hosp Pharm
; 2023 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37188505
7.
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.
Exp Hematol Oncol
; 12(1): 63, 2023 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37480095
8.
Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.
Sci Rep
; 13(1): 13427, 2023 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37596388
9.
[COVID-19 and patients with cancer: Experiment of a French comprehensive cancer center]. / Première vague COVID-19 : expérience d'un centre de lutte contre le cancer.
Bull Cancer
; 108(6): 571-580, 2021 Jun.
Artigo
em Francês
| MEDLINE | ID: mdl-33896587
10.
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy.
Drugs R D
; 21(4): 399-406, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34562258
11.
Advanced cancer and COVID-19 comorbidity: medical oncology-palliative medicine ethics meetings in a comprehensive cancer centre.
BMJ Support Palliat Care
; 2021 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33927013
12.
Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials.
JCO Precis Oncol
; 3: 1-10, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35100670
13.
[Fluoropyrimidines cardiac toxicity: 5-fluorouracil, capecitabine, compound S-1 and trifluridine/tipiracil]. / La toxicité cardiaque des fluoropyrimidines : 5-fluorouracile, capécitabine, le composé S-1 et le trifluridine/tipiracil.
Bull Cancer
; 105(7-8): 707-719, 2018.
Artigo
em Francês
| MEDLINE | ID: mdl-29960638
14.
Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.
ESMO Open
; 3(3): e000339, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29636991
15.
[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10]. / Nouvelle AMM européenne : pembrolizumab en association à la chimiothérapie en première ligne des carcinomes épidermoïdes de l'Åsophage ou des adénocarcinomes de la jonction Åsogastrique HER2-négatifs non résécables/métastatiques et présentant une expression de PDL1 avec un CPS≥10.
Bull Cancer
; 109(2): 111-113, 2022 02.
Artigo
em Francês
| MEDLINE | ID: mdl-34998526
16.
[New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)]. / Nouvelle AMM européenne : nivolumab en association à la chimiothérapie en première ligne de traitement de l'adénocarcinome de l'Åsophage HER2-négatif avec une expression de PD-L1 (CPS≥5).
Bull Cancer
; 109(2): 109-110, 2022 02.
Artigo
em Francês
| MEDLINE | ID: mdl-34996599
17.
Hyperprogressive Disease After Pembrolizumab Treatment in Advanced Epstein-Barr Virus-Associated Gastric Adenocarcinoma With ERBB2 Amplification.
JCO Precis Oncol
; 5: 370-377, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34994599